Log in

Pfenex Stock Price, News & Analysis (NYSEAMERICAN:PFNX)

$8.88
+0.32 (+3.74 %)
(As of 10/14/2019 01:24 AM ET)
Today's Range
$8.52
Now: $8.88
$9.00
50-Day Range N/A
52-Week Range
$3.13
Now: $8.88
$10.20
Volume332,605 shs
Average Volume205,045 shs
Market Capitalization$280.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
CIKN/A
Phone+1-858-3524400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees71
Market Cap$280.59 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.


Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. The biotechnology company had revenue of $2.81 million for the quarter, compared to the consensus estimate of $5.65 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

3 brokerages have issued 12 month price targets for Pfenex's shares. Their predictions range from $17.00 to $17.00. On average, they expect Pfenex's share price to reach $17.00 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

News headlines about PFNX stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfenex earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Pfenex.

Are investors shorting Pfenex?

Pfenex saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 529,100 shares, an increase of 7.1% from the August 30th total of 493,800 shares. Based on an average daily trading volume, of 298,800 shares, the short-interest ratio is currently 1.8 days. Approximately 1.7% of the company's stock are sold short. View Pfenex's Current Options Chain.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 51)
  • Dr. Hubert C. Chen, Advisor (Age 50)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 55)

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $8.88.

How big of a company is Pfenex?

Pfenex has a market capitalization of $280.59 million. Pfenex employs 71 workers across the globe.View Additional Information About Pfenex.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  183 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel